First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin
Condition(s):Advanced Recurrent Malignant Pleural Epithelioid Mesothelioma; Advanced Recurrent Malignant Peritoneal Epithelioid Mesothelioma; Advanced Recurrent Serous Ovarian Cancer; Advanced Pancreatic Ductal Adenocarcinoma (Optional, Dose Expansion, Not Initiated)Last Updated:March 20, 2023Completed